Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Andapharm, LLC
WARNING LETTER
•Andapharm, LLC•July 18, 2018

Andapharm, LLC – FDA Warning Letter, Jul 18, 2018

Record Details

The FDA inspected ANDAPharm, LLC's drug manufacturing facility from July 10 to 18, 2018, identifying significant violations of current good manufacturing practice (CGMP) regulations (21 CFR parts 210 and 211), rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B). The firm's August 3, 2018, response was deemed inadequate. Key violations included failure to establish and follow adequate written procedures for equipment cleaning and maintenance (21 CFR 211.67(b)), which was a repeat violation from 2012 and 2016 inspections. The firm also failed to establish and follow an adequate stability testing program (21 CFR 211.166(a)), another repeat violation. Additionally, ANDAPharm failed to maintain separate or defined areas to prevent contamination or mix-ups (21 CFR 211.42(c)), and did not follow written procedures for production and process control, including proper documentation at the time of performance (21 CFR 211.100(b)). The FDA noted the firm's quality systems are inadequate and, due to repeat violations, strongly recommended engaging a CGMP consultant. As a contract manufacturer, ANDAPharm is responsible for the quality of drugs produced. The firm must promptly correct these violations within 15 working days to avoid potential legal action, including seizure, injunction, and withholding of drug application approvals or export certificates.

Company
Andapharm, LLC
Inspection date
July 18, 2018
Product type
Drugs
Office
Dallas District Office
People
  • Monica R. Maxwell (Program Division Director)
  • Renee Alsobrook
View Company Profile

ID · 3dac399d-3df7-42e4-8f8b-76a60dc787c6

Violation Codes8
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.67(b)21 CFR 211.166(a)21 CFR 211.42(c)21 CFR 211.100(b)21 CFR 211.34

Full citation text and observation details available on the Dashboard.

Other documents for Andapharm, LLC
  • WARNING_LETTER - 2014-10-10October 10, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Andapharm, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.